Gary Stetz was named Chief Financial Officer of Hepion Pharmaceuticals, Inc., effective October 9, 2026. As of November 6, 2026, Hepion Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 2, 2026 to October 9, 2026, naming 1 appointment (Form 8-K, October 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Hepion Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Gary Stetz · Role: Chief Financial Officer · Effective: 2026-10-09 · 8-K, 2026-10-09
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-20
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-02
Hepion Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-02 to 2026-10-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Hepion Pharmaceuticals, Inc. files it.
Also on the record for Hepion Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 26, 2026 | Stake report, Schedule 13D, by Gravitas Collective Corp. | 19.9% of the class | 5%+ stakes | Source |
| October 21, 2026 | Stake report, Schedule 13G/A, by Kenneth Rickel | 7.2% of the class | 5%+ stakes | Source |
| October 6, 2026 | Acquired Gravitas Life Sciences, LLC | $2.25M | Acquisition | Source |
| September 16, 2026 | Stake report, Schedule 13D/A, by KI Holdings Ltd. | 10.2% of the class | 5%+ stakes | Source |
| September 15, 2026 | Stake report, Schedule 13G, by Kenneth Rickel | 5.7% of the class | 5%+ stakes | Source |
| August 20, 2026 | Stake report, Schedule 13D, by Gary Stetz | 5.7% of the class | 5%+ stakes | Source |
| August 20, 2026 | Stake report, Schedule 13D, by Sireesh Appajosyula | 5.7% of the class | 5%+ stakes | Source |
| August 20, 2026 | Stake report, Schedule 13D/A, by Vincent LoPriore | 26.2% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13D, by Black Global 5 LLC | 11.1% of the class | 5%+ stakes | Source |
| August 5, 2026 | Form D, private offering | $3.06M sold | Form D page | Source |
| May 1, 2026 | Stake report, Schedule 13D, by Vincent LoPriore | 21.46% of the class | 5%+ stakes | Source |
| April 22, 2026 | Form D, private offering | $700K sold | Form D page | Source |
Selling to them or working with them? See who runs Hepion Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Hepion Pharmaceuticals, Inc. and the records around it.
The people at Hepion Pharmaceuticals, Inc.
- Gary Stetz, Sireesh Appajosyula and Vincent LoPriore are also named on 6 other Form D filings: Canton Strategic Holdings, Inc. (Apr 2026), Tharimmune, Inc. (Jul 2025)
Hepion Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Acquisition Oct 2026
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- S.H.N. Financial Investments Ltd. also filed stake reports on 19 other companies: PRF Technologies Ltd. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch Hepion Pharmaceuticals, Inc.
Get an email when Hepion Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Hepion Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Hepion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hepion Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-09 | In | Chief Financial Officer | 2026-10-09 | 8-K, 2026-10-09 | |
| 2026-08-20 | Reported | not named in the filing | 8-K, 2026-08-20 | ||
| 2026-07-02 | Reported | not named in the filing | 8-K, 2026-07-02 |
Who leads Hepion Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Gary Stetz, appointed, effective 2026-10-09 (filed 2026-10-09).
New leaders reset buying decisions — get the Full Report on Hepion Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Hepion Pharmaceuticals, Inc. (free up to 3)
Find people with the same kind of experience as the Chief Financial Officer at Hepion Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Hepion Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Gary Stetz, Chief Financial Officer, effective 2026-10-09
On October 9, 2026, the board of directors (the "Board") of the Company appointed Gary Stetz, the Company's former Interim Chief Executive Officer, to serve as the Company's Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company's Chief Executive Officer, in each case effective as of October 9, 2026.
- Dr. Appajosyula, age 51, has served as a member of the Company's board of directors since March 2026.
- From July 2021 until June 2026, Dr. Appajosyula was a director of Canton Strategic Holdings, Inc. and was Chief Operating Officer from July 2023.
- From April 2020 until June 2023, he has served as SVP, Corporate Development and Operations of 9 Meters Biopharma, Inc. ("9 Meters"), a company focused on rare and unmet needs in gastrointestinal patient populations developing compounds with unique gastrointestinal biology, and since 2018 he has served as Managing Member of Highpoint Pharmaceuticals, LLC, a pharmaceutical research and development company.
- In addition, since 2015, Mr. Appajosyula has served as Managing Partner of Channel BioConsulting, LLC, a company that assists in enhancing search and evaluation efforts for complementary assets to be added to existing portfolios of biopharmaceutical companies.
- Mr. Stetz currently serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm with more than 1,000 corporate clients.
- In addition, Mr. Stetz has been Chief Executive Officer of President Street Global, LLC since August 2026.
- From March 2026 until October 2026, Mr. Stetz was interim CEO of the Company and has been a director of the Company since March 2026.
Reported
On August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company") approved the appointment of James Liddy as a director of the Company, effective immediately.
Reported
On July 1, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company") approved the appointment of Danina Fisher and Gary S. Stetz, II as directors of the Company, effective immediately.
Hepion Pharmaceuticals, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Hepion Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.